Clinical Trial Update: SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting completion and posted results for SGI-110 (guadecitabine) in patients with myelodysplastic syndromes, chronic myelomonocytic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• SGI-110 (guadecitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: MDS, CMML | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-23